Literature DB >> 19535990

Lewy body pathology in normal elderly subjects.

William R Markesbery1, Gregory A Jicha, Huaichen Liu, Frederick A Schmitt.   

Abstract

Lewy bodies and Lewy neurites are the hallmark neuropathologic findings in Parkinson disease, Parkinson disease with dementia, dementia with Lewy bodies, and other alpha-synucleinopathies. They have also been described in the brains of normal older individuals and referred to as incidental Lewy body disease. The purpose of this study was to determine the prevalence of Lewy bodies and Lewy neurites (Lewy body pathology [LBP]) in 139 autopsies from our normal volunteer control group of the University of Kentucky Alzheimer's Disease Center. All subjects were followed longitudinally and were cognitively normal and without any type of movement disorder, neuropsychiatric features, or other CNS findings. The brains of 33 of 139 normal subjects contained LBP in various regions. The most common regions involved were the medulla (26%), amygdala (24%), pons (20%), and midbrain (20%). No mean statistical differences were found between those with and without LBP on any demographic or cognitive variable, Braak stage, or neurofibrillary tangle and neuritic plaque quantitation. An explanation for the high prevalence of LBP in our elderly, well-educated study group is not clear, although it does not seem to be related to aging or the presence of Alzheimer disease pathology. Overall, our findings support the concept that incidental Lewy body disease most likely represents preclinical or presymptomatic Parkinson disease, Parkinson disease with dementia, or dementia with Lewy bodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19535990      PMCID: PMC2704264          DOI: 10.1097/NEN.0b013e3181ac10a7

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  34 in total

1.  Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study.

Authors:  Yoshinobu Wakisaka; Akiko Furuta; Yumihiro Tanizaki; Yutaka Kiyohara; Mitsuo Iida; Toru Iwaki
Journal:  Acta Neuropathol       Date:  2003-08-02       Impact factor: 17.088

2.  Age-associated prevalence and risk factors of Lewy body pathology in a general population.

Authors:  Kurt A Jellinger
Journal:  Acta Neuropathol       Date:  2003-08-02       Impact factor: 17.088

3.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

4.  Where does parkinson disease pathology begin in the brain?

Authors:  Kelly Del Tredici; Udo Rüb; Rob A I De Vos; Jürgen R E Bohl; Heiko Braak
Journal:  J Neuropathol Exp Neurol       Date:  2002-05       Impact factor: 3.685

5.  Brain donation in normal aging: procedures, motivations, and donor characteristics from the Biologically Resilient Adults in Neurological Studies (BRAiNS) Project.

Authors:  F A Schmitt; M M Wetherby; D R Wekstein; C M Dearth; W R Markesbery
Journal:  Gerontologist       Date:  2001-12

6.  Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry.

Authors:  R L Hamilton
Journal:  Brain Pathol       Date:  2000-07       Impact factor: 6.508

7.  Alpha-synuclein pathology is highly dependent on the case selection.

Authors:  L Parkkinen; H Soininen; M Laakso; I Alafuzoff
Journal:  Neuropathol Appl Neurobiol       Date:  2001-08       Impact factor: 8.090

8.  Lewy bodies are not increased in progressive supranuclear palsy compared with normal controls.

Authors:  Y Tsuboi; J E Ahlskog; H Apaydin; J E Parisi; D W Dickson
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

9.  Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease.

Authors:  Laura Parkkinen; Hilkka Soininen; Irina Alafuzoff
Journal:  J Neuropathol Exp Neurol       Date:  2003-04       Impact factor: 3.685

10.  Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease.

Authors:  G A Jicha; F A Schmitt; E Abner; P T Nelson; G E Cooper; C D Smith; W R Markesbery
Journal:  Neurobiol Aging       Date:  2008-11-20       Impact factor: 4.673

View more
  67 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

Review 2.  Pathologic correlates of dementia in individuals with Lewy body disease.

Authors:  Joshua A Sonnen; Nadia Postupna; Eric B Larson; Paul K Crane; Shannon E Rose; Kathleen S Montine; James B Leverenz; Thomas J Montine
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

Review 3.  α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.

Authors:  Sushil K Singh; Aloke Dutta; Gyan Modi
Journal:  Future Med Chem       Date:  2017-06-20       Impact factor: 3.808

Review 4.  Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder.

Authors:  Fernando Calahorro; Manuel Ruiz-Rubio
Journal:  Invert Neurosci       Date:  2011-11-08

5.  Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition.

Authors:  Kathryn P Riley; Gregory A Jicha; Daron Davis; Erin L Abner; Gregory E Cooper; Nancy Stiles; Charles D Smith; Richard J Kryscio; Peter T Nelson; Linda J Van Eldik; Frederick A Schmitt
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

6.  Ecology of the aging human brain.

Authors:  Joshua A Sonnen; Karen Santa Cruz; Laura S Hemmy; Randall Woltjer; James B Leverenz; Kathleen S Montine; Clifford R Jack; Jeffrey Kaye; Kelvin Lim; Eric B Larson; Lon White; Thomas J Montine
Journal:  Arch Neurol       Date:  2011-08

Review 7.  Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Authors:  Alberto J Espay; Joaquin A Vizcarra; Luca Marsili; Anthony E Lang; David K Simon; Aristide Merola; Keith A Josephs; Alfonso Fasano; Francesca Morgante; Rodolfo Savica; J Timothy Greenamyre; Franca Cambi; Tritia R Yamasaki; Caroline M Tanner; Ziv Gan-Or; Irene Litvan; Ignacio F Mata; Cyrus P Zabetian; Patrik Brundin; Hubert H Fernandez; David G Standaert; Marcelo A Kauffman; Michael A Schwarzschild; S Pablo Sardi; Todd Sherer; George Perry; James B Leverenz
Journal:  Neurology       Date:  2019-02-12       Impact factor: 9.910

8.  The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals.

Authors:  Alexandra M Wennberg; Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Melissa E Murray; Mary M Machulda; Leonard Petrucelli; Michelle M Mielke; Clifford R Jack; David S Knopman; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson; Keith A Josephs
Journal:  Neurobiol Aging       Date:  2019-01-21       Impact factor: 4.673

Review 9.  Primary Age-Related Tauopathy (PART): Addressing the Spectrum of Neuronal Tauopathic Changes in the Aging Brain.

Authors:  Richard A Hickman; Xena E Flowers; Thomas Wisniewski
Journal:  Curr Neurol Neurosci Rep       Date:  2020-07-14       Impact factor: 5.081

Review 10.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.